MCB
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, B.
Right arrow Articles by Zhang, X.-k.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, B.
Right arrow Articles by Zhang, X.-k.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, February 2000, p. 957-970, Vol. 20, No. 3
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Orphan Receptor COUP-TF Is Required for Induction of Retinoic Acid Receptor beta , Growth Inhibition, and Apoptosis by Retinoic Acid in Cancer Cells

Bingzhen Lin, Guo-quan Chen, Dongmei Xiao, Siva Kumar Kolluri, Xihua Cao, Hong Su, and Xiao-kun Zhang*

Cancer Research Center, The Burnham Institute, La Jolla, California 92037

Received 31 August 1999/Returned for modification 1 October 1999/Accepted 5 November 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Retinoic acid receptor beta  (RARbeta ) plays a critical role in mediating the anticancer effects of retinoids. Expression of RARbeta is highly induced by retinoic acid (RA) through a RA response element (beta RARE) that is activated by heterodimers of RARs and retinoid X receptors (RXRs). However, RARbeta induction is often lost in cancer cells despite expression of RARs and RXRs. In this study, we provide evidence that orphan receptor COUP-TF is required for induction of RARbeta expression, growth inhibition, and apoptosis by RA in cancer cells. Expression of COUP-TF correlates with RARbeta induction in a variety of cancer cell lines. In addition, stable expression of COUP-TF in COUP-TF-negative cancer cells restores induction of RARbeta expression, growth inhibition, and apoptosis by RA, whereas inhibition of COUP-TF by expression of COUP-TF antisense RNA represses the RA effects. In a transient transfection assay, COUP-TF strongly induced transcriptional activity of the RARbeta promoter in a RA- and RARalpha -dependent manner. By mutation analysis, we demonstrate that the effect of COUP-TF requires its binding to a DR-8 element present in the RARbeta promoter. The binding of COUP-TF to the DR-8 element synergistically increases the RA-dependent RARalpha transactivation function by enhancing the interaction of RARalpha with its coactivator CREB binding protein. These results demonstrate that COUP-TF, by serving as an accessory protein for RARalpha to induce RARbeta expression, plays a critical role in regulating the anticancer activities of retinoids.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Retinoids, a class of natural and synthetic vitamin A analogs, exert profound effects on many biological processes, including cell proliferation and differentiation, vision, reproduction, morphogenesis, and pattern formation, both in normal and transformed cells (9, 30). They have been well recognized as promising agents for the prevention of human cancers (9, 13, 30, 58). Their therapeutic potential has also received a great amount of attention, since all-trans-retinoic acid (RA) showed dramatic antitumor effects in patients with acute promyelocytic leukemia (58). However, retinoid resistance associated with many different types of cancer has prevented the further application of retinoids (13, 58).

The effects of retinoids are mainly mediated by two classes of nuclear receptors, the RA receptors (RARs) and retinoid X receptors (RXRs) (18, 34, 67). 9-cis-RA is a high-affinity ligand for both RARs and RXRs, whereas all-trans-RA is a ligand for only RARs. RARs and RXRs are encoded by three distinct genes (alpha , beta , and gamma ) and are members of the steroid/thyroid hormone receptor superfamily, which function as ligand-activated transcription factors (18, 34, 67). RARs and RXRs primarily function as RXR-RAR heterodimers that bind to a variety of RA response elements (RAREs) and regulate their transactivation function (18, 34, 67). Transcriptional activation by retinoid receptors requires a carboxy-terminal helical region, termed activation function-2, that forms part of the ligand-binding pocket and that undergoes a conformational change required for the recruitment of coactivator proteins, such as CREB binding protein (CBP) (17). This appears to provide a direct link to the core transcriptional machinery and modulates chromatin structure (62).

In addition to retinoid receptors, a number of orphan receptors whose ligands are unknown have been implicated in the regulation of the retinoid response (25, 47). One of the factors is COUP-TF. COUP-TF is encoded by two distinct genes, COUP-TFI (ear-3) (36, 56) and COUP-TFII (ARP-1) (22). Both genes show an exceptionally high degree of homology, and their expression patterns often overlap, suggesting that they may serve redundant functions (47). However, each factor possesses its own distinct expression profile during development (47). A null mutation of COUP-TFI resulted in defects in neurogenesis, axon guidance, and arborization (46), whereas deletion of COUP-TFII resulted in striking defects in angiogenesis, vascular remodeling, and fetal heart development (41). COUP-TF was originally shown to stimulate gene transcription (40). However, subsequent work has demonstrated that COUP-TF can repress the transcription induced by a number of nuclear receptors including RARs, thyroid hormone receptors, and vitamin D receptor (3, 20, 24, 53, 59). It has been recently reported that COUP-TFs can function as positive regulators for many different genes. In the arrestin gene promoter, a DR-7 element mediates the positive transcriptional effect of COUP-TF (32), while in the other genes, such as the trout estrogen receptor (23), the phosphoenolpyruvate carboxykinase (10), the vHNF1 (45), the human immunodeficiency virus long terminal repeat (49), and the NGFI-A (44) genes, the positive-transcription function of COUP-TF is mediated through its interaction with other transcriptional factors. For the NGFI-A gene, COUP-TF enhances transcription by recruiting coactivator SRC-1 through its interaction with SP-1 (44).

Retinoids exert their anticancer activities mainly through their abilities to modulate the growth, differentiation, and apoptosis of cancer cells. Recent studies have indicated that RARbeta plays a critical role in mediating the growth-inhibitory effect of retinoids in many different types of cancer cells, including those of breast cancer (27, 29), lung cancer (28), ovarian cancer (42), prostate cancer (2), neuroblastoma (6), renal cell carcinoma (11), pancreatic cancer (16), liver cancer (26), and head and neck cancer (70). Expression of RARbeta in RARbeta -negative cancer cells restored RA-induced growth inhibition and apoptosis, whereas inhibition of RARbeta expression in RARbeta -positive cancer cells abolished RA effects (27-29). In addition, transgenic mice expressing RARbeta antisense sequences showed increased incidence of lung tumor (1), whereas suppression of RARbeta expression was responsible for diminished anticancer activities of retinoids in animals (57). Moreover, up-regulation of RARbeta is associated with a positive clinical response to retinoids in patients with premalignant oral lesions (31, 50).

The finding that a deletion of the short arm of chromosome 3p24, close to where the RARbeta gene maps, occurs with high frequency in human tumors (21, 38) led to studies on abnormalities of the RARbeta gene and its expression. These studies revealed a high frequency of abnormal expression of the RARbeta gene, but not of genes of the other RAR subtypes, in human cancer cell lines and primary human cancer tissues (8, 14, 15, 39, 55, 68, 69). Thus, the loss of RARbeta may be a key mechanism by which cancer cells escape normal growth control and a contributing factor in cancer development (35, 63). Indeed, it has been shown that loss of RARbeta is an early event in carcinogenesis (43, 60, 63, 64) and may be involved in liver cancer development (4).

How RARbeta expression is regulated and how its expression is lost in cancer cells remain largely unknown and are subjects of intensive study. Expression of RARbeta is highly induced by RA through a RARE (beta RARE) present in its promoter (5, 12, 51) that is activated by RAR-RXR heterodimers (54, 65). However, we and others have recently demonstrated that expression of RARs and RXRs is not sufficient to render RARbeta expression responsive to RA (19, 37, 55, 68). In the majority of lung cancer cell lines, RARbeta expression could not be induced by RA, despite expression of RARs and RXRs (68). Similarly, retinoid refractoriness occurs during lung carcinogenesis despite the expression of functional retinoid receptors (19). Thus, factors other than RARs and RXRs are required for RA to induce RARbeta expression.

We have previously demonstrated that expression of COUP-TF is positively correlated with RARbeta induction and growth inhibition by RA in lung cancer cell lines (61). In this study, we further investigated the effect of COUP-TF in the regulation of RA-dependent RARbeta induction and the underlying molecular mechanism. Our results demonstrate that COUP-TF is required for RA to induce RARbeta expression, growth inhibition, and apoptosis in cancer cells. In addition, our studies showed that COUP-TF could strongly induce transcriptional activity of the RARbeta promoter in a RA- and RARalpha -dependent manner through its binding to a DR-8 element present in the promoter. Furthermore, we observed that COUP-TF, through its interaction with RARalpha , strongly enhanced the interaction of RARalpha with its coactivator CBP, demonstrating that COUP-TF induces RARbeta promoter transcription by acting as an accessory protein for RARalpha to recruit its coactivator.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Cell culture. CV-1, HeLa, MDA-MB231, and MDA-MB468 cells were grown in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum (FCS). Calu-6, HT-1376, J82, SK-MES-1, and 5637 cells were maintained in minimal essential medium supplemented with 10% FCS. H292, H520, H460, H596, H441, and H661 cells were grown in RPMI 1640 supplemented with 10% FCS. A-549 cells were maintained in F12 medium supplemented with 10% FCS.

Plasmid constructions. The RARbeta promoter reporter (-745RARbeta CAT) has been described previously (12). The coding sequence of RARalpha was inserted into the multiple cloning sites of the eukaryotic expression vector pECE (65). The insertion of COUP-TFI cDNA into pRC/CMV vector (Invitrogen, San Diego, Calif.) in sense and antisense orientations followed the procedure described previously (29). The RARbeta promoter deletion mutants were created by cloning BamHI-flanked PCR products derived from -745RARbeta promoter into the pBluescript chloramphenicol acetyltransferase (CAT) plasmid (12). The forward primers were as follows: for the -516RARbeta promoter, CATGGATCCTAGCCATTCTCGTTCTACAGT; for the -300RARbeta promoter, CATGGATCCAGAAGTTGGTGCTCAACGTGA; for the -126RARbeta promoter, CATGGATCCAGCTCTGTGAGAATCCTGGG. The oligonucleotide CATGGATCCTACCCCGACGGTGCCCAGA was used as the reverse primer for the above mutants. The -60RARbeta promoter mutant was constructed by subcloning a SmaI/BamHI-flanked fragment from the RARbeta promoter into the pBluescript CAT plasmid. The COUP-TF-RE and beta RARE mutant constructs were generated by ligating the mutated RARbeta promoter PCR products into the pBluescript CAT vector. The following primers were used to incorporate the appropriate mutations: TCCCCCGGGCTGCTAACCTTCAAATGACCCAAGTGACATCACCAA for COUP-TF-RE/M1, TCCCCCGGGCTGCTAACCTTCAAATGACCCAACTAGTCGAGCATCACCAA for COUP-TF-RE/M2, TCCCCCGGGTAGAACTCACCGAAAGTTCAC for beta RARE/M1, and TCCCGGGTAGGGTTCACCGAGTTCAC for beta RARE/M2. The COUP-TF-RE-tk-CAT reporter was obtained by inserting the DR-8 synthetic oligonucleotide into the BamHI site of pBL-CAT2 (65). For COUP-TFII receptor mutations, pBSCOUP-TFII deletion mutants were obtained by cloning PCR products from COUP-TFII into pBluescript (Stratagene). The oligonucleotide CATCGAGTGCGTGAGACGGGAAGCGGTG was used as the forward primer, while the reverse primers were as follows: GCCATGTCGACTCAGTTAAAACTGCTGCC for pBS-COUP-TFII/Delta 7, TGCTGGTCGACTATAACATATCCCGGATG for pBS-COUP-TFII/Delta 14, and ACCTGTCGACTAGACGAAAAACAATTGC for pBS COUP-TFII/Delta 30. pBS-COUP-TFII/Delta 80 was obtained by digesting pBS-COUP-TFII with HindIII, whereas pBS-COUP-TFII/Delta 108 was obtained by digesting pBS-COUP-TFII with HindII. pBS-COUP-TFII/Delta 179 was generated by subcloning an EcoRI/PstI COUP-TFII fragment into EcoRI/PstI-digested pBluescript. The orientations and sequences of all mutants were confirmed by DNA sequencing. To generate COUP-TFIIDelta DBD, the N terminus coding sequence of COUP-TFII was amplified by PCR with a primer (CCGCTTCCCGTCTCACGCACTCGATGTG) corresponding to COUP-TFII cDNA sequences that preceded the DNA binding domain, whereas the C terminus coding sequence of COUP-TFII was amplified with a primer (CATCGAGTGCGTGAGACGGGAAGCGGTG) corresponding to COUP-TFII cDNA sequences right after the DNA binding domain. The resulting PCR products were then ligated to generate a COUP-TFII mutant with the DNA binding domain deleted. The COUP-TFII cDNA deletion mutants were also cloned into pCDNA3 (Invitrogen) for a transient transfection assay.

Preparation of COUP-TF proteins. Receptor proteins for COUP-TFI and COUP-TFII were synthesized by an in vitro transcription and translation system using rabbit reticulocyte lysate (Promega) as described previously (65). The relative amounts of the translated proteins were determined by using [35S]methionine-labeled protein in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), quantitating the amount of incorporated radioactivity and normalizing it relative to the content of methionine in each protein.

Transient and stable transfection assay. CV-1 cells were plated at 105 cells per well in a 24-well plate 16 to 24 h before transfection, as described previously (66). For cancer cells, 5 × 105 cells were seeded in a six-well plate. A modified calcium phosphate precipitation procedure was used for transient transfection and is described elsewhere (66). Briefly, 700 ng of reporter plasmid, 100 ng of beta -galactosidase (beta -Gal) expression vector (pCH 110; Pharmacia), and various amounts of COUP-TF expression vector and RARalpha were mixed with carrier DNA (pBluescript) to 1,000 ng of total DNA per well. CAT activity was normalized for transfection efficiency to the corresponding beta -Gal activity. For stable transfection, the pRc/CMV-COUP-TFI recombinant plasmid was stably transfected into MDA-MB231 cells, and pRC/CMV-antisense-COUP-TFI was stably transfected into J82 cells by the calcium phosphate precipitation method, and stable clones were screened with G418 (GIBCO BRL, Grand Island, N.Y.) as described previously (29). Southern blotting and Northern blotting were used to determine the integration and expression of transfected cDNA, respectively.

Gel retardation assay. Oligonucleotides used for the gel retardation assay are described in the text. For the protein-DNA binding assay, in vitro-translated protein (1 to 4 µl, depending on the translation efficiency) was incubated with the 32P-labeled oligonucleotides in a 20-µl reaction mixture containing 10 mM HEPES buffer, pH 7.9, 50 mM KCl, 1 mM dithiothreitol, 2.5 mM MgCl2, 10% glycerol, and 1 µg of poly(dI-dC) at 25°C for 20 min. Unprogrammed reticulocyte lysate was used to maintain equal protein concentrations in all reaction mixtures. Each reaction mixture was then loaded on a 5% nondenaturing polyacrylamide gel containing 0.5× TBE (1× TBE is 0.089 M Tris-borate, 0.088 M boric acid, and 0.002 M EDTA).

GST pull-down assay. To prepare the glutathione S-transferase (GST)-receptor fusion protein, the receptor cDNA (COUP-TFI or RARalpha ) was cloned in frame into the expression vector pGEX-2T (Pharmacia). The fusion protein was expressed in bacteria by the procedure provided by the manufacturer and was analyzed by a gel retardation assay and Western blotting (data not shown). To analyze the interaction between RARalpha and COUP-TFI and between COUP-TFI and CBP, the fusion protein was immobilized to glutathione-Sepharose beads. For a control, the vector protein (GST), prepared under the same conditions, was also immobilized. The beads were preincubated with bovine serum albumin (1 mg/ml) at room temperature for 5 min. 35S-labeled, in vitro-synthesized receptor proteins (2 to 5 µl, depending on translation efficiency) were then added to the beads. The beads were then continuously rocked for 1 h at 4°C in a final volume of 200 µl in EBC buffer (140 mM NaCl, 0.5% NP-40, 100 mM NaF, 200 µM sodium orthovanadate, and 50 mM Tris, pH 8.0). After being washed five times with NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris [pH 8.0], 0.5% NP-40), the bound proteins were analyzed by SDS-PAGE.

Growth inhibition assays. To determine the effect of all-trans-RA on the viability of the stable transfectants, cells were seeded at 1,000 per well in a 96-well plate and treated with various concentrations of all-trans-RA for 6 days. Media were changed every 48 h. The number of viable cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay as described previously (29). For the anchorage-independent growth assay, 30,000 cells/60-mm-diameter dish in culture medium containing 10% FCS, 0.3% agar (Difco, Detroit, Mich.), and 10-7 M RA were plated onto an already-hardened 0.6% agar underlayer in medium supplemented with 10% FCS. The plates were incubated for 21 days in a 5% CO2 incubator. Colonies with more than 40 cells were counted with a microscope.

Apoptosis assay. Cells were treated with or without all-trans-RA (10-6 M). Forty-eight hours later, cells were trypsinized, washed with phosphate-buffered saline (PBS; pH 7.4), and fixed in 1% formaldehyde in PBS. After being washed in PBS, cells were resuspended in 70% ice-cold ethyl alcohol and immediately stored at -20°C overnight. Cells were then labeled with biotin-16-dUTP by terminal deoxynucleotidyltransferase (TdT) and stained with avidin-fluorescein isothiocyanate (Boehringer, Mannheim, Germany). Fluorescently labeled cells were analyzed with a FACScater-plus as described previously (29). Representative histograms are shown.

Northern blotting. For Northern blot analysis, total RNAs were prepared with an RNeasy Mini Kit (Qiagen, Hilden, Germany). Thirty micrograms of total RNA from different cell lines treated with or without all-trans-RA (10-6 M) was analyzed by Northern blotting. An EcoRI fragment in the ligand binding domain of RARbeta or a PstI fragment in the ligand binding domain of COUP-TFI cDNA was used as a probe to study the expression of RARbeta or COUP-TFII, respectively. The PstI fragment could detect the expression of COUP-TFI and COUP-TFII due to the high degree of homology of both receptor genes in the region. To determine that equal amounts of RNA were used, the expression of beta -actin was studied.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Correlation between COUP-TF expression and RARbeta induction by RA. We recently showed that expression of COUP-TF is required for RA sensitivity in certain lung cancer cell lines (61). To examine to what degree COUP-TF is involved in the regulation of RARbeta expression, we analyzed the expression of COUP-TF in various cancer cell lines, including breast cancer cell lines ZR-75-1, MDA-MB468, MDA-MB231, and T-47D, bladder cancer cell lines J82, HT-1376, 5637, and SCaBER, and lung cancer cell lines H520, H292, Calu-6, H460, H596, A-549, H441, SK-MES-1, and H661. A PstI fragment in the ligand binding domain of COUP-TF was used as a probe. The probe could detect transcripts for COUP-TFI and COUP-TFII. When the expression of COUP-TFs was compared with RA-induced RARbeta expression, we found a perfect correlation between COUP-TFI expression and the ability of RA to induce RARbeta in breast cancer cell lines (Fig. 1). COUP-TFI was expressed in ZR-75-1 and T-47D cell lines, in which RARbeta expression was highly induced by RA. In contrast, COUP-TF transcripts were not detected in MDA-MB468 and MDA-MB231 cell lines that did not show a clear induction of RARbeta by RA. In bladder cancer cell lines, RARbeta was highly induced by RA in COUP-TFI-positive J82 cells but not in COUP-TFI-negative 5637 and SCaBER cells. Although HT-1376 cells expressed COUP-TFI, we did not observe any RARbeta expression. This is due to lack of RARalpha expression in these cells (see Discussion). A correlation was also observed in lung cancer cell lines, except SK-MES-1 and H661 lines. COUP-TFI and COUP-TFII were highly expressed in RARbeta -inducible cell lines Calu-6, H460, and H596 but not in RARbeta -noninducible H520, H292, A549, and H441 cell lines. These observations suggest that expression of COUP-TF may be required for RA to induce RARbeta expression in different types of cancer cells.


View larger version (62K):
[in this window]
[in a new window]
 
FIG. 1.   Correlation between COUP-TF expression and RARbeta induction by RA in human breast cancer (A), bladder cancer (B), and lung cancer (C) lines. Total RNAs were prepared from the indicated cancer cell lines treated with or without all-trans-RA (10-6 M) for 24 h and analyzed for the expression of COUP-TFI and RARbeta . For a control, the expression of beta -actin is shown.

Levels of COUP-TFI expression modulate RA-dependent RARbeta expression, growth inhibition, and apoptosis. To further determine the requirement of COUP-TF for RA-dependent activation of RARbeta gene expression, we stably expressed COUP-TFI in COUP-TF-negative MDA-MB231 breast cancer cells. Two stable clones (MB231/COUP#10 and MB231/COUP#16) that expressed a high level of transfected COUP-TFI (Fig. 2A) were subjected to an analysis of RARbeta gene expression in the absence or presence of RA. Under the conditions used, we did not detect any expression of the RARbeta transcript in the parental MDA-MB231 cells in either the absence or presence of RA (Fig. 2B), consistent with our previous observation (29). However, RA treatment strongly induced RARbeta expression in the COUP-TFI-stable clones, not in the MDA-MB231 cells transfected with the empty vector (MB231/vector) (Fig. 2B). This suggests that expression of COUP-TFI confers on MDA-MB231 cells sensitivity to RA regulation of RARbeta expression. When the effect of the stable transfection of COUP-TFI on growth of MDA-MB231 cells was analyzed, we observed that RA, which was unable to regulate the growth of the parental MDA-MB231 cells, could strongly inhibit the growth of the clones carrying stably transfected COUP-TFI, with about 41 and 54% inhibition in MB231/COUP#16 and MB231/COUP#10 cells, respectively, when they were treated with 10-6 M RA for 6 days (Fig. 2C). The growth-inhibitory effect of RA is specific to COUP-TFI expression since RA had no effect on the growth of MB231/vector cells. We also examined the effect of COUP-TFI expression on apoptosis induction by RA. The TdT assay showed extensive DNA fragmentation in MB231/COUP#10 and MB231/COUP#16 cells but not in MDA-MB231 and MB231/vector cells. About 2% apoptotic cells were detected in cultures of MDA-MB231 and MB231/vector cells when they were treated with 10-6 M RA for 2 days. However, the same RA treatment resulted in about 36 and 24% apoptotic cells in cultures of MB231/COUP#10 and MB231/COUP#16 cells, respectively (Fig. 2D), suggesting that expression of COUP-TFI could allow RA to induce apoptosis of MDA-MB231 cells. Thus, expression of COUP-TFI in COUP-TF-negative cancer cells can restore their response to RA effects on RARbeta expression, growth inhibition, and apoptosis.


View larger version (28K):
[in this window]
[in a new window]
 
FIG. 2.   Stable expression of COUP-TF in COUP-TF-negative, RA-resistant MDA-MB231 cells enhances the effect of RA on RARbeta induction, growth inhibition, and apoptosis induction. (A) Expression of transfected COUP-TFI in MDA-MB231 cells. COUP-TFI was stably transfected into MDA-MB231 cells, and expression of transfected COUP-TFI was determined by Northern blotting. For comparison, cells transfected with the empty vector (MB231/vector) were used. (B) Expression of RARbeta gene in MDA-MB231 cells and MDA-MB231/COUP-TF stable clones. Total RNAs were prepared from MDA-MB231, its COUP-TFI stable clones (MB231/COUP#16 and MB231/COUP#10), and MDA-MB231 transfected with the empty vector (MB231/vector). Cells were treated with or without all-trans-RA (10-6 M) for 24 h and analyzed for the expression of RARbeta by Northern blotting. In the control, the expression of beta -actin is shown. (C) Growth-inhibitory effect of RA in MDA-MB231 and MDA-MB231/COUP-TF stable clones. Cells were seeded at 1,000 cells per well in a 96-well plate and treated with the indicated concentrations of all-trans-RA for 6 days. The numbers of viable cells were determined by the MTT assay. (D) Effect of RA on apoptosis of MDA-MB231 cells and MDA-MB231/COUP-TF stable clones. Cells were treated with or without all-trans-RA (10-6 M) for 48 h, and DNA fragmentations were then determined by the TdT assay. Representative histograms show relative apoptotic cell numbers.

To further study the role of COUP-TF, we stably expressed COUP-TFI antisense cDNA in COUP-TF-positive J82 bladder cancer cells. A stable clone that expressed a high level of COUP-TFI antisense RNA (J82/A-COUP) (Fig. 3A) was analyzed for the effect of RA on RARbeta expression (Fig. 3B), growth inhibition (Fig. 3C), and apoptosis induction (Fig. 3D). RARbeta expression was highly induced by RA in J82 cells. However, the ability of RA to induce RARbeta expression was significantly reduced in J82/A-COUP cells but not in J82 cells expressing the empty vector (J82/vector) (Fig. 3B). Thus, inhibition of COUP-TF expression reduced the ability of RA to induce RARbeta expression. When the effect of RA on growth inhibition was analyzed, we observed that RA could effectively inhibit the growth of J82 cells, with 55% inhibition when they were treated with 10-6 M RA for 6 days. A similar growth-inhibitory effect of RA (46% inhibition) was also observed in J82/vector cells. However, the effect of RA was dramatically reduced in J82/A-COUP cells, with only 12% inhibition upon RA treatment (Fig. 3C). Consistent with the role of RARbeta in apoptosis induction, we observed that RA strongly induced apoptosis of J82 and J82/vector cells, with 43.8 and 36.2% apoptotic cells, respectively, as determined by the TdT assay (Fig. 3D). However, the apoptosis-inducing effect of RA was significantly repressed by COUP-TFI antisense RNA expression, as only 13.8% apoptotic cells were detected among J82/A-COUP cells. Together, these data demonstrate that inhibition of COUP-TFI expression by COUP-TFI antisense RNA represses the ability of RA to induce RARbeta expression, growth inhibition, and apoptosis in COUP-TF-positive cancer cells.


View larger version (26K):
[in this window]
[in a new window]
 
FIG. 3.   Inhibition of COUP-TF expression by stable expression of COUP-TF anti-sense RNA in COUP-TF-positive J82 cells represses effect of RA on RARbeta expression, growth inhibition, and apoptosis induction. (A) Expression of transfected COUP-TFI antisense RNA in J82 cells. COUP-TFI cDNA was stably transfected into J82 cells, and expression of transfected COUP-TFI antisense RNA in a selected stable clone (J82/A-COUP) was analyzed by Northern blotting. For comparison, the parental J82 cells and J82 cells stably transfected with the empty vector (J82/vector) were used. (B) Inhibition of RARbeta induction by RA by stable expression of COUP-TFI antisense RNA in J82 cells. Total RNAs were prepared from J82, J82/vector, and J82/A-COUP cells treated with or without all-trans-RA (10-6 M) for 24 h and analyzed for the expression of RARbeta by Northern blotting. The expression of beta -actin is shown for the control. (C) Inhibition of RA-induced growth inhibition by stable expression of COUP-TF antisense RNA in J82 cells. Cells were seeded at 1,000 cells per well in a 96-well plate and treated with the indicated concentrations of all-trans-RA for 6 days. The numbers of viable cells were determined by the MTT assay. (D) Inhibition of RA-induced apoptosis of J82 cells by COUP-TF antisense RNA. Cells were treated with or without all-trans-RA (10-6 M) for 48 h, and DNA fragmentations were then determined by the TdT assay. Representative histograms show relative apoptotic cell numbers.

To further characterize the effect of the transfected COUP-TFI gene, the COUP-TFI-transfected MDA-MB231 cells were analyzed for their anchorage-independent growth in soft agar. As shown in Fig. 4, the growth of MDA-MB231 and MB231/vector cells in soft agar was not clearly affected by RA treatment. However, RA dramatically inhibited the growth of MB231/COUP#10 and MB231/COUP#16 cells. These data suggest that expression of COUP-TFI could confer on RA the ability to inhibit the transforming activity of cancer cells.


View larger version (37K):
[in this window]
[in a new window]
 
FIG. 4.   Inhibition of anchorage-independent growth of MDA-MB231 cells by COUP-TF gene expression. (A) Visualization of colonies formed in the soft agar by parental MDA-MB231, MB231/COUP#10, MB231/COUP#16, and MB231/vector cells in the presence or absence of RA (10-7 M). (B) Quantitation of colonies formed by parental MDA-MB231, MB231/COUP#10, MB231/COUP#16, and MB231/vector cells. Colonies formed by MB231/COUP#10, MB231/COUP#16, MB231/vector, and parental MDA-MB231 cells in the presence or absence of all-trans-RA (10-7 M) were scored and expressed as percentages of colonies formed by cells treated with control solvent.

COUP-TF enhances RARbeta promoter activity in a RARalpha - and RA-dependent manner. To investigate the possibility that COUP-TFI induced RARbeta expression by activating RARbeta promoter transcription, a reporter construct that contains the RARbeta promoter sequences from -745 to +162 linked to the CAT reporter gene (-745RARbeta CAT) (12) was transiently transfected into CV-1 cells. Cotransfection of the RARalpha expression vector induced RARbeta promoter activity in response to RA (Fig. 5A), while cotransfection of the COUP-TFII expression vector slightly enhanced the reporter gene activity. However, when both COUP-TFII and RARalpha were cotransfected, a synergistic induction of RARbeta promoter activity in response to RA was observed. Induction of RARbeta promoter activity by RARalpha was enhanced from 16-fold to 44-fold when 20 ng of COUP-TFII was cotransfected, while a 56-fold induction was observed when 50 ng of COUP-TFII was cotransfected. A similar observation was also made with COUP-TFI (data not shown). We also investigated the effect of COUP-TFII in HT-1376 bladder cancer cells, which express a low level of COUP-TF (Fig. 1) and an undetectable level of RARalpha (our unpublished result). Cotransfection of the RARalpha expression vector slightly induced RARbeta promoter activity in response to RA in these cells, while cotransfection of COUP-TFII did not show any effect on RARbeta promoter activity (Fig. 5B). The lack of COUP-TFII activity is likely due to loss of RARalpha expression in these cells (see Discussion). When COUP-TFII was cotransfected with RARalpha , the RARalpha -induced RARbeta activity was strongly increased, compared to a 5-fold induction of RARbeta promoter activity by RARalpha alone and a 24-fold induction when both RARalpha and COUP-TFII were present. Similar results were also obtained when COUP-TFI was used and in other cancer cell lines, such as HeLa cells and MDA-MB231 cells (data not shown). Together, our data demonstrate that expression of COUP-TF is required for efficient induction of RARbeta promoter activity by RA in a RARalpha -dependent manner.


View larger version (17K):
[in this window]
[in a new window]
 
FIG. 5.   COUP-TF enhances RARbeta promoter activity in a RARalpha - and RA-dependent manner. (A) Activation of RARbeta promoter activity by COUP-TF in CV-1 cells. RARbeta promoter reporter (-745RARbeta CAT; 700 ng) was cotransfected with the indicated amounts of expression vector for COUP-TFII and RARalpha into CV-1 cells. Cells were treated with or without all-trans-RA (10-6 M) for 24 h and assayed for CAT activity. (B) Activation of RARbeta promoter in HT-1376 bladder cancer cells by COUP-TF. Cells were transfected with 1,500 ng of -745RARbeta CAT reporter gene together with expression vectors for RARalpha (300 ng) and/or COUP-TFII (300 ng). Cells were treated with or without all-trans-RA (10-6 M) and 24 h later were assayed for CAT activity. Data shown represent the means of three independent experiments.

A DR-8 element in the RARbeta promoter mediates the COUP-TF effect. To identify DNA sequences responsible for the COUP-TF effect in the RARbeta promoter, we generated a series of 5' deletion mutants of the RARbeta promoter (Fig. 6A). The resulting RARbeta promoter fragments were fused to the CAT reporter gene and analyzed for the effect of COUP-TFII in enhancing RA-induced RARalpha activity in CV-1 cells (Fig. 6B). Deletion of 229 bp from the 5' end of the RARbeta promoter (-516RARbeta CAT) did not have any effect on the ability of COUP-TFII to enhance RARbeta activity. Recently, it was shown that COUP-TF could positively regulate gene transcription through an SP-1 site (44, 49). There is an SP-1 site (from -378 to -370) in the RARbeta promoter that could bind the SP-1 protein (data not shown). However, COUP-TFII retained its ability to induce RARalpha activity in -300RARbeta CAT and -126RARbeta CAT reporters in spite of deletion of the SP-1 binding site. This suggests that the effect of COUP-TFII on the RARbeta promoter is not mediated through the SP-1 binding site. Further deletion of 66 bp from -126RARbeta CAT, however, completely abolished the COUP-TFII effect (Fig. 6B). This suggests that position -126 to -60 of the RARbeta promoter contains a COUP-TF response element (COUP-TF-RE). Inspection of the fragment between positions -126 and -60 revealed a direct repeat of AGGTCA-like motifs with 8-bp spacing (DR-8) located from -99 to -78 (Fig. 7A). COUP-TF is known to bind to a variety of nuclear receptor response elements containing AGGTCA-like motifs arranged in different orientations with different spacings (53). We therefore examined whether the DR-8 element in the RARbeta promoter could bind to COUP-TF. An oligonucleotide containing the sequence was synthesized and analyzed by gel retardation assay for its COUP-TF binding activity. As shown in Fig. 7B, in vitro-synthesized COUP-TFI or COUP-TFII formed a strong complex with the sequence. For comparison, RARalpha , RXRalpha , or the RARalpha -RXRalpha heterodimer did not exhibit any binding. The complex formed by COUP-TFI could be abolished by a 50-fold-excess amount of TREpal or CRBPII-RARE, which are known to bind with high affinity to COUP-TFs (53), while the same amount of SP-1 oligonucleotide did not show any effect on the binding. Thus, COUP-TF may exert its effect on the RARbeta promoter through its binding to the DR-8 element.


View larger version (20K):
[in this window]
[in a new window]
 
FIG. 6.   Identification of COUP-TF response element in the RARbeta promoter. (A) Schematic representation of the RARbeta promoter deletion mutants. The Sp-1 binding site, beta RARE, and the TATA box are indicated. (B) Effect of COUP-TFII on RA-induced RARalpha transactivation activity of various RARbeta promoter deletion mutants. CV-1 cells were transfected with 700 ng of CAT reporter gene containing the indicated RARbeta promoter fragment together with expression vectors for COUP-TFII (50 ng) and RARalpha (20 ng). Cells were then treated with or without all-trans-RA (10-6 M) and 24 h later were assayed for CAT activity. -, without receptor cotransfection. Data shown represent the means of three independent experiments.


View larger version (47K):
[in this window]
[in a new window]
 
FIG. 7.   Analysis of COUP-TF binding on the COUP-TF-RE in the RARbeta promoter. (A) Sequence of the COUP-TF-RE. Arrows indicate the AGGTCA-like core motifs. (B) Binding of COUP-TF on the COUP-TF-RE. In vitro-synthesized COUP-TFI or COUP-TFII was incubated with 32P-labeled oligonucleotide containing the COUP-TF-RE and analyzed by a gel retardation assay. For comparison, the binding of RARalpha , RXRalpha , and the RARalpha -RXRalpha heterodimer was analyzed. For the competition assay, a 50-fold excess amount of the indicated oligonucleotide was used. -, without competitor; solid arrowheads, specific COUP-TF binding complex; open arrowheads, nonspecific binding complex.

To study the role of the COUP-TF binding sequence, we investigated the effect of COUP-TF-RE mutations on COUP-TF activity in a RARbeta promoter. The COUP-TF-RE was mutated by changing either the spacing between two core motifs (COUP-TF-RE/M1) or the core motif sequences (COUP-TF-RE/M2) (Fig. 8A). The mutated COUP-TF-REs were first analyzed for their binding to COUP-TF proteins. Unlike their binding to the wild-type COUP-TF-RE, the binding of COUP-TFI or COUP-TFII to the mutated COUP-TF-REs was largely impaired (Fig. 8B). We then introduced the same mutations into the -745RARbeta CAT reporter by PCR. The resulting RARbeta promoter reporter mutants, -745RARbeta /COUP-TF-RE/M1/CAT and -745RARbeta /COUP-TF-RE/M2/CAT, were then analyzed by transient transfection assay for the effect of COUP-TF-RE mutations on COUP-TFII activity. As shown in Fig. 8C, mutations of COUP-TF-RE did not affect the ability of RARalpha to induce reporter transcription since cotransfection of RARalpha showed similar degrees of induction of transcription of both the mutated RARbeta promoter and the wild-type promoter (compare with Fig. 5). However, the enhancing effect of COUP-TFII on RARalpha activity was largely reduced in the mutated RARbeta promoter reporters. These results demonstrate that the DR-8 element is required for COUP-TF to enhance RA- and RARalpha -dependent activation of RARbeta promoter transcription.


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 8.   COUP-TF-RE is required for positive regulation of RARbeta promoter activity by COUP-TF. (A) Mutations of the COUP-TF-RE. Depicted are the COUP-TF-RE sequence and its mutations (boldfaced). (B) The mutated COUP-TF-REs failed to bind to the COUP-TF protein. The indicated COUP-TF-RE mutant was synthesized and analyzed for its binding to COUP-TF by the gel retardation assay. In vitro-synthesized COUP-TF protein was incubated with 32P-labeled COUP-TF-RE or the mutated COUP-TF-RE and analyzed by a gel retardation assay. Solid arrowhead, specific COUP-TAF binding complex; open arrowhead, nonspecific binding. (C) Mutations of COUP-TF-RE abolished the effect of COUP-TF on the RARalpha transactivation function in the RARbeta promoter. The COUP-TF-RE in the RARbeta promoter was mutated by PCR. The resulting RARbeta promoter mutants (-745RARbeta CAT/COUP-TF-RE/M1 and -745RARbeta CAT/COUP-TF-RE/M2) were analyzed by transient transfection assay in CV-1 cells for their effect on COUP-TF activity. CV-1 cells were transfected with the 700-ng reporter gene together with the indicated amounts of expression vectors for RARalpha and COUP-TFII. Cells were treated with or without all-trans-RA (10-6 M) and 24 h later were assayed for CAT activity. CAT activity was normalized for transfection efficiency to the corresponding beta -Gal activity. Data shown represent the means of three independent experiments.

DNA binding of COUP-TF is required for its transactivation function. To determine which region of COUP-TF is required for the binding of the DR-8 element and the activation of the RARbeta promoter, a number of COUP-TFII mutants were generated (Fig. 9A) and analyzed for their binding to the element (Fig. 9B) and their enhancing effect on RARalpha activity in the -745RARbeta CAT reporter (Fig. 9C). Deletion of seven amino acids from the C-terminal end of the COUP-TFII protein did not affect the binding of COUP-TF-RE (Fig. 9B). The same mutant also bound strongly to TREpal as the wild-type receptor. However, removal of an additional seven amino acid residues resulted in a mutant (COUP-TFII/Delta 14) that could not bind either to COUP-TF-RE or to TREpal. As expected, other mutants analyzed, including COUP-TFII/Delta 30, COUP-TFII/Delta 80, COUP-TFII/Delta 108, and COUP-TFII/Delta 179 (Fig. 9A), did not exhibit any detectable binding on both elements (Fig. 9B). When the effect of these mutants on RARalpha transactivation function in -745RARbeta CAT was analyzed, we observed that removal of as few as 14 amino acid residues from the C-terminal end of the COUP-TFII protein completely abolished the enhancing effect of COUP-TFII (Fig. 9C). Other C-terminal deletion mutants, which could not bind to the DR-8 element, also failed to enhance RARalpha activity (data not shown). A mutant with the DNA binding domain deleted (COUP-TF/Delta DBD) was also unable to enhance RARalpha activity (Fig. 9C). Thus, the DNA binding of COUP-TF is essential for its enhancing effect on RARalpha activity.


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 9.   DNA binding of COUP-TF is required for its enhancing effect on RARalpha activity in the RARbeta promoter. (A) Schematic representation of COUP-TF mutants. The DNA binding domain and the ligand domain of COUP-TFII as well as the A/B, C, D, and E/F domains are indicated. (B) Binding of the COUP-TFII mutants to COUP-TF-RE and TREpal. In vitro-synthesized COUP-TFII or the indicated COUP-TFII deletion mutant was incubated with 32P-labeled COUP-TF-RE or TREpal as indicated and analyzed by a gel retardation assay. The arrowheads indicate the specific COUP-TF binding complexes. (C) Effect of the COUP-TFII mutants on RARalpha activity in the RARbeta promoter. CV-1 cells were transfected with 700 ng of -745RARbeta CAT reporter gene together with the expression receptor for RARalpha (20 ng) and the indicated amount of COUP-TFII or COUP-TFII deletion mutants. Cells were treated with or without all-trans-RA (10-6 M) for 24 h and were assayed for CAT activity. Data shown represent the means of three independent experiments.

beta RARE is required for the DR-8 element to confer the RA- and RARalpha -dependent transactivation function of COUP-TF. To further determine the role of the DR-8 element in mediating the COUP-TF transactivation function, we cloned the sequence into the pBLCAT2 plasmid, which contains the thymidine kinase (TK) promoter linked with the CAT reporter gene (65). The resulting construct, COUP-TF-RE-tk-CAT, was transiently transfected into CV-1 cells. Surprisingly, we did not see any effect of COUP-TFII on reporter transcription either in the absence or presence of RA, indicating that the binding of COUP-TFII could not transactivate the reporter (Fig. 10). Cotransfection of the RARalpha expression vector did not have any effect on the reporter activity, either in the absence or presence of RA, consistent with our gel retardation assay showing lack of RARalpha binding to the DR-8 element (Fig. 7B). Furthermore, cotransfection of COUP-TFII and RARalpha expression vectors failed to activate reporter transcription. These data demonstrate that the DR-8 element alone is not sufficient to confer the RA- and RARalpha -dependent transactivation function of COUP-TF observed in the RARbeta promoter.


View larger version (21K):
[in this window]
[in a new window]
 
FIG. 10.   COUP-TF-RE alone is not sufficient to confer the activation function of COUP-TF. COUP-TF-RE was cloned into pBLCAT2, which contained the TK promoter linked with the CAT gene. The resulting reporter construct (COUP-TF-RE-tk-CAT) was analyzed for its response to the COUP-TF effect by transient transfection assay. The reporter gene (100 ng) was cotransfected with the indicated amounts of expression receptor for RARalpha and COUP-TFII into CV-1 cells. After transfection, cells were treated with or without all-trans-RA (10-6 M) and 24 h later were assayed for CAT activity. Data shown represent the means of three independent experiments.

The above data suggest that sequences other than the DR-8 element in the RARbeta promoter are required for the RA- and RARalpha -dependent transactivation function of COUP-TFs. We therefore analyzed the involvement of beta RARE by mutational analysis since it is the only known sequence in the RARbeta promoter that mediates the RA effect (12). Two beta RARE mutations were made by changing either the core motif sequences (beta RARE/M1) or the spacing between two core motifs (beta RARE/M2) (Fig. 11A). Both beta RARE mutants failed to bind to RARalpha , RXRalpha , or RARalpha -RXRalpha heterodimers in the gel retardation assay (Fig. 11B). The RARbeta promoter reporter constructs with mutated beta RARE, -745RARbeta CAT/beta RARE/M1 and -745RARbeta CAT/beta RARE/M2, were then generated by PCR and analyzed by a transient transfection assay (Fig. 11C). We first examined the effect of RARalpha on the mutated RARbeta promoter. Compared to that of the parental RARbeta promoter (-745RARbeta CAT), the transactivation function of RARalpha was significantly reduced in the mutated RARbeta promoters. Interestingly, RARalpha could still induce transcriptional activities of both RARbeta promoter mutants, although its binding on the mutated beta RAREs was completely abolished (Fig. 11B). Since we did not observe any effect of RARalpha on the mutated beta RAREs when they were fused to the TK promoter (data not shown), the observed effect of RARalpha is likely due to the presence of another RARE in the RARbeta promoter (our unpublished observation). Nevertheless, when the effect of COUP-TFII on both promoter mutants was analyzed, we did not observe any enhancement of RARalpha activity, suggesting that intact beta RARE, capable of binding with the RARalpha -RXRalpha heterodimer, is essential for the transactivation function of COUP-TF. Thus, both beta RARE and the DR-8 element are required for the RA- and RARalpha -dependent transactivational function of COUP-TF in the RARbeta promoter.


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 11.   beta RARE in the RARbeta promoter is required for the enhancing effect of COUP-TF on RARalpha activity in the RARbeta promoter. (A) Schematic representation of the beta RARE mutations. Depicted are wild-type beta RARE in the RARbeta promoter and its mutations (boldface). Arrows indicate the care motifs of the beta RARE. (B) Effect of beta RARE mutations on retinoid receptor binding. In vitro-synthesized RARalpha and RXRalpha were incubated with 32P-labeled beta RARE or the mutated beta RARE and analyzed by a gel retardation assay. The arrowhead indicates specific RAR-RXR heterodimer binding. (C) Mutations of the beta RARE impair the enhancing effect of COUP-TF on RARalpha activity in the RARbeta promoter. Mutations in the beta RARE of the RARbeta promoter were introduced by PCR as described in Materials and Methods. The resulting RARbeta promoter mutants (-745RARbeta CAT/beta RARE/M1 and -745RARbeta CAT/beta RARE/M2) were analyzed by transient transfection assay for the effect of COUP-TF. CV-1 cells were transfected with 700 ng of reporter gene together with the indicated amounts of expression vectors for COUP-TFII and RARalpha . Cells were then treated with or without all-trans-RA (10-6 M) and 24 h later were assayed for CAT activity. Data shown represent the means of three independent experiments.

COUP-TF enhances recruitment of CBP by RARalpha . The transactivation function of nuclear receptors requires their interaction with receptor coactivators (62), such as CBP (17). The transactivation function of COUP-TF could be due to its interaction with CBP. We therefore investigated whether COUP-TFI could interact with CBP by the GST pull-down assay. Under the conditions used, we did not observe a clear interaction between COUP-TFI and CBP (Fig. 12A), consistent with a previous report (44). This demonstrates that the transactivation function of COUP-TFI is unlikely to be mediated through its direct interaction with CBP. The facts that the transactivation function of COUP-TF is RARalpha and RA dependent and requires beta RARE suggest that the effect of COUP-TF may be mediated by RARalpha , which is known to interact with CBP (17). We then incubated GST-COUP-TFI with CBP in the presence of in vitro-synthesized RARalpha . As shown in Fig. 12A, a significant amount of CBP was pulled down by the GST-COUP-TFI fusion protein when RARalpha was present. We also determined whether COUP-TF could enhance the interaction between RARalpha and CBP. As shown in Fig. 12A, CBP was slightly pulled down by the GST-RARalpha fusion protein. However, when GST-RARalpha was mixed with in vitro-synthesized COUP-TFI protein, a significant amount of CBP was pulled down. The observation that both RARalpha and COUP-TFI are required for their maximum interaction with CBP suggests that COUP-TFI may interact with RARalpha . Indeed, in vitro-synthesized RARalpha was efficiently pulled down by GST-COUP-TFI, but not by the GST control protein (Fig. 12B), demonstrating that COUP-TFI could directly interact with RARalpha . Thus, COUP-TF may facilitate the RARalpha -CBP interaction by interacting with RARalpha , resulting in a RARalpha conformation favorable for CBP interaction.


View larger version (18K):
[in this window]
[in a new window]
 
FIG. 12.   COUP-TF enhances recruitment of CBP by RARalpha . (A) COUP-TF enhances interaction of RAR and CBP. COUP-TFI or RARalpha protein was synthesized in bacteria with pGEX-2T (Pharmacia). The GST-COUP-TFI or GST-RARalpha fusion protein was immobilized on glutathione-Sepharose beads, while the same amount of GST was also immobilized on beads as a control. 35S-labeled CBP was then mixed with beads and in vitro-synthesized RARalpha (for GST-COUP-TFI) or in vitro-synthesized COUP-TFI (for GST-RARalpha ) in the presence of 10-6 M all-trans-RA. After extensive washing, the bound proteins were analyzed by SDS-PAGE. The input proteins are shown for comparison. (B) COUP-TFI interacts with RARalpha . To analyze the interaction between COUP-TF and RARalpha , 35S-labeled RARalpha was mixed with GST-COUP-TFI fusion protein on beads. After extensive washing, the bound proteins were analyzed by SDS-PAGE. As a comparison, the input proteins are shown. (C) COUP-TF increases the effect of CBP on RARalpha activity. The indicated amounts of expression vector for RARalpha , COUP-TFII, and CBP were cotransfected with RARbeta promoter into CV-1 cells. Cells were treated with or without all-trans-RA (10-6 M) for 24 h and then were assayed for CAT activity. The corresponding beta -Gal activity was normalized as a control.

We next analyzed whether COUP-TF could influence the transcriptional effect of CBP on RARalpha activity in CV-1 cells. Cotransfection of the CBP expression vector slightly enhanced RARalpha transcriptional activity in the RARbeta promoter. However, when COUP-TFII and RARalpha were cotransfected, the effect of CBP on RARbeta promoter activity was greatly increased (Fig. 12C). Such an effect of COUP-TF on CBP activity, together with our GST pull-down results, strongly suggests that COUP-TF, through its binding to the DR-8 element and interacting with RARalpha , may function as a bridge protein to facilitate the interaction between beta RARE binding receptors and CBP, resulting in an enhanced RA-dependent transcription of the RARbeta promoter.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

RARbeta plays a crucial role in the mediating growth-inhibitory effect of retinoids, and lack of its expression contributes to retinoid resistance in many different types of cancer cells. Expression of RARbeta is induced by RA through binding of RAR-RXR heterodimers to the beta RARE in the RARbeta promoter. However, expression of RAR and RXR in cancer cells is not sufficient to account for induction of RARbeta by RA. Here, we provide convincing evidence that orphan receptor COUP-TF is required for RA to induce RARbeta expression, growth inhibition, and apoptosis in cancer cells and that loss of COUP-TF expression is the main factor contributing to the lack of RARbeta expression in cancer cells. In addition, we show that COUP-TF synergistically increases the RA-dependent RARalpha transactivation function in the RARbeta promoter through its binding to a DR-8 element in the promoter, which enhances the interaction of RARalpha with its coactivator CBP.

Expression of COUP-TF is required for efficient RARbeta induction by RA in cancer cells. Several lines of evidence provided in this study demonstrate that expression of COUP-TF is required for efficient RARbeta induction by RA in cancer cells. First, expression of COUP-TF is positively correlated with induction of RARbeta by RA in breast cancer, lung cancer, and bladder cancer cell lines (Fig. 1). A perfect correlation was observed in breast cancer cell lines, while a close correlation was found in lung cancer and bladder cancer cell lines. This observation is consistent with previous studies (33, 47, 48) demonstrating that RARbeta and COUP-TFII are coexpressed in motor neurons. In addition, our stable expression of COUP-TFI in COUP-TF-negative MDA-MB-231 breast cancer cells (Fig. 2) showed that expression of COUP-TFI could restore the ability of RA to induce RARbeta expression. Furthermore, inhibition of COUP-TF expression by stable expression of COUP-TFI antisense RNA in COUP-TF-positive J82 cancer cells reduced the ability of RA to induce RARbeta expression (Fig. 3). Finally, our transient transfection assays clearly demonstrated that COUP-TF could activate the RARbeta promoter in response to RA when RARalpha was expressed (Fig. 5). Thus expression of COUP-TF is required for RA to effectively induce RARbeta expression, and loss of COUP-TF in cancer cells may be one of the important mechanisms responsible for the lack of RARbeta expression in cancer cells.

Effect of COUP-TF on growth inhibition and apoptosis induction by RA. RA is known to inhibit the growth of and induce apoptosis in cancer cells, in part due to its induction of RARbeta (27-29). Our observation that COUP-TF expression is required for RARbeta induction by RA implies that COUP-TF is also involved in RA-induced growth inhibition and apoptosis signaling. This is clearly shown by our stable transfection of COUP-TFI in COUP-TF-negative MDA-MB231 cells (Fig. 2). MDA-MB231 breast cancer cells are RA resistant due to lack of RARbeta induction by RA (29). When COUP-TFI was stably expressed in these cells, their growth was strongly inhibited by RA (Fig. 2C). Furthermore, the cells underwent extensive apoptosis in response to RA treatment (Fig. 2D). The observation that RARbeta was strongly induced in the COUP-TFI stable clones (Fig. 2B) suggests that the observed growth inhibition and apoptosis induction are likely mediated by the induced RARbeta expression. The involvement of COUP-TF in the regulation of RA-dependent growth inhibition and apoptosis induction is further supported by our stable expression of COUP-TFI antisense RNA in COUP-TF-positive J82 bladder cancer cells (Fig. 3). Expression of COUP-TFI antisense RNA in this RA-sensitive cell line dramatically reduced the ability of RA to induce growth inhibition (Fig. 3C) and apoptosis of the cells (Fig. 3D), which was accompanied by a reduced level of RARbeta expression (Fig. 3B). Together, our results demonstrate that COUP-TF may play a critical role in the regulation of the growth-inhibitory effect of retinoids in cancer cells.

Transactivation function of COUP-TF requires both COUP-TF-RE and beta RARE in the RARbeta promoter. By mutation analysis, we demonstrated that a DNA sequence comprising two AGGTCA-like core motifs arranged as a direct repeat with 8-bp spacing (the DR-8 element) is required for the COUP-TF effect. The DR-8 element bound strongly with COUP-TF (Fig. 7). Interestingly, the binding of COUP-TF did not repress the RARbeta promoter. Instead, it is essential for the transactivation function of COUP-TF. Deletion of the sequence from the RARbeta promoter completely abolished the effect of COUP-TF on RARbeta promoter activity (Fig. 6). In addition, mutations in the DR-8 element that impaired the binding of COUP-TF reduced the COUP-TF effect on the enhancement of RAR